Bias in artificial intelligence impacts drug development: AiCure

Artificial intelligence and other forms of advanced data analysis frequently are viewed as completely impartial and free of bias. However, when the people that set up the processes inadvertently introduce bias, the results can be impacted. Rich Christie, chief medical officer of AiCure, recently connected with Outsourcing-Pharma to talk about the problems that bias in AI can lead to in trials and development. OSP: Could you please share some perspective on bias around clinical trial data? Specifically, how can AI and other advanced analytical tools (largely seen as objective) be slanted toward one group and/or against another?